OR WAIT null SECS
January 30, 2020
Clinical manufacturing of the therapy will take place at Lonza's Houston, TX, and Netherlands cGMP manufacturing sites.
The new 1800-m2 building houses more than 50 employees and features non-GMP laboratory space and a GMP analytical laboratory.
January 29, 2020
The new facility, to be operated under the newly formed CDMO, The Center for Breakthrough Medicines, will be located in King of Prussia, PA, and will increase manufacturing capacity for cell and gene therapies.
January 27, 2020
Drug development contract services company PPD announces initial public offering.
January 24, 2020
Propess (dinoprostone) from Ferring Pharmaceuticals has achieved approval from the Minister of Health, Labour, and Welfare (MHLW) in Japan, making it the first pharmacological treatment for cervical ripening to be approved in the country for more than 20 years.
January 22, 2020
The new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise.
The fully integrated, pre-qualified, pre-installed aseptic filling facility can be shipped globally for drug development and the manufacturing of personalized medicines and clinical trial supplies.
The facility is now equipped to handle commercial manufacturing of a sterile injectable product in a pre-filled syringe presentation.
Frank Sorce will be taking on the role of regional business development director for Tedor Pharma.
Mereo BioPharma Group and Oncologie have entered a global licensing agreement for the development and commercialization of navicixizumab.